Novartis Portugal Revenue and Competitors
Estimated Revenue & Valuation
- Novartis Portugal's estimated annual revenue is currently $20.9M per year.
- Novartis Portugal's estimated revenue per employee is $224,774
Employee Data
- Novartis Portugal has 93 Employees.
- Novartis Portugal grew their employee count by 8% last year.
Novartis Portugal's People
Name | Title | Email/Phone |
---|
Novartis Portugal Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 221 | 16% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 91 | -10% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 16 | -6% | $114.3M | N/A |
#8 | $7.2M | 28 | -7% | N/A | N/A |
#9 | $13.7M | 51 | -9% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Novartis Portugal?
Estamos a reimaginar a medicina para melhorar e prolongar a vida das pessoas. Como uma empresa global líder em medicamentos, usamos a ciência inovadora e tecnologias digitais para criar terapêuticas transformadoras em áreas com grandes necessidades médicas. Em Portugal, a nossa equipa tem 350 pessoas e estamos sediados no Taguspark, em Porto Salvo. Consulte aqui as Normas da Comunidade: http://bit.ly/NormasLinkedInNovartispt Aviso de Privacidade páginas de LinkedIn: http://bit.ly/AvisoPrivNovartisPT
keywords:N/AN/A
Total Funding
93
Number of Employees
$20.9M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Novartis Portugal News
2022-04-20 - Telix Pharmaceuticals : Appendix 4C and Activities Report for March 2022
quarter
3 Novartis release 23 March 2022. ... Greece and Cyprus (BIOKOSMOS S.A.), Poland (Synektik Pharma Sp. Zo. o), Portugal (Avanço), Sweden,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 97 | 24% | N/A |
#2 | N/A | 103 | 58% | N/A |
#3 | $22.1M | 110 | 8% | N/A |
#4 | N/A | 114 | 23% | N/A |
#5 | $18.1M | 117 | 48% | N/A |